Just as a diseased heart has numerous negative effects on kidney function, renal insufficiency can significantly impair cardiac function.¹

So it is no surprise that those with chronic kidney disease (CKD) have a dramatically increased risk for cardiovascular mortality.² In fact, they are much more likely to die from cardiovascular causes than they are from end- stage renal disease.³

With a high prevalence of obstructive coronary disease a probable cause, increased efforts for the aggressive diagnosis and treatment of coronary artery disease in the CKD population are warranted.²

Yet the fact is, CKD patients are less likely to receive optimal medical therapy or intervention than those without compromised renal function.⁴

It seems likely that risks to the kidney associated with the use of angiographic contrast material may be a factor deterring physicians from undertaking potentially life-saving interventions.⁴

If you would like to discuss how isosmolar Visipaque can help you to manage the cardiorenal risk of procedures in patients with CKD, please click here